Compare CDMOs with respiratory drug manufacturing expertise for metered-dose inhalers, dry powder inhalers, nebulizer solutions, and nasal sprays. Filter by device type, scale, and certifications.
Respiratory drug manufacturing is device-intensive. The active ingredient is only half the product -- the delivery device (metered-dose inhaler, dry powder inhaler, soft mist inhaler, nebulizer) determines drug deposition in the lungs and ultimately clinical efficacy. CDMOs in this space need both pharmaceutical formulation expertise and device/packaging engineering capabilities.
Particle engineering is the critical science. Inhaled drugs require precisely controlled particle size distributions (typically 1-5 microns for deep lung delivery). Micronization, spray drying, and engineered particle technologies determine the respirable fraction. CDMOs should demonstrate particle size control via laser diffraction (Malvern), cascade impaction (NGI), and delivered dose uniformity testing across the product lifecycle.
Combination products add regulatory complexity. Inhalers are regulated as drug-device combination products by the FDA (21 CFR Part 4) and require both pharmaceutical cGMP and device quality system (ISO 13485) compliance. The CDMO must manage two quality systems simultaneously. For generic inhalers, demonstrating bioequivalence requires in vitro similarity studies (aerodynamic particle size distribution, delivered dose uniformity) and often in vivo pharmacokinetic studies.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.